drugset / Trial / NCT03107091

Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites

NCT03107091

Phase 2 Completed 6 enrolled BioVie Inc.
NaSingle-groupOpen-labelTreatment

Summary

Low-dose continuous infusion of terlipressin will be administered to six cirrhotic patients with refractory ascites.

Timeline

Start
2017-07-15
Primary completion
2019-04-01
Completion
2019-04-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Terlipressin Peptide 2 mg Intravenous

Indications